FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate

20Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: FDG PET-CT is generally not suitable for diagnosing prostate cancer because of low glycolysis of the tumor cells. Neuroendocrine differentiation of the prostate cancer is often associated with early visceral metastasis and dismal prognosis, which is resulted from changed metabolic and regulatory pathways. Case presentation: A case is reported in this paper that FDG PET-CT demonstrates intense uptake of neuroendocrine tumor of the prostate and multiple metastases. Conclusion: There is high glycolysis and strong FDG-avidity of neuroendocrine tumor of the prostate, which is similar to that of high grade of neuroendocrine tumor in other tissue and organs. In some selected cases of prostate neuroendocrine cancer, whole body FDG PET-CT may be helpful for detection of metastatic disease. © 2008 Liu; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Liu, Y. (2008). FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate. World Journal of Surgical Oncology, 6. https://doi.org/10.1186/1477-7819-6-64

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free